Clostridium difficile-related pancolitis in lung-transplanted patients with cystic fibrosis

Patriarchi, F.; Rolla, M.; Maccioni, Francesca; Menichella, A.; Scacchi, C.; Ambrosini, Anna; Costantino, A.; Quattrucci, Serena

doi:10.1111/j.1399-0012.2010.01316.x

Cited by 16 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[41][42][43][44][45][46] There is some controversy as to the role of stomach acid suppression in CDI pathogenesis. Recent data have suggested that circumventing the potential protective effect of stomach acid, for example, through the use of postpyloric enteral feeding or the use of PPIs or histamine 2 receptor blockers, may lead to a 2-to 3-fold increased risk of acquisition of CDI.…”

Section: Article Highlightsmentioning

confidence: 98%

Clostridium difficile Infection: New Insights Into Management

Khanna

Pardi

2012

Mayo Clinic Proceedings

123

113

View full text Add to dashboard Cite

Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the leading 3 hospital-acquired infections in the United States, along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In the past 2 decades, there has been an increase in the incidence, severity, and recurrence rates of C difficile infection, all of which are associated with poor outcomes. In addition, several novel risk factors and newer treatment methods are emerging, including fidaxomicin therapy, treatment using monoclonal antibodies, and fecal microbiota transplantation, that have shown promise for the treatment of C difficile infection. This review focuses on the changing epidemiology, risk factors, and newer methods for treatment of C difficile infection.

show abstract

Section: Article Highlightsmentioning

confidence: 98%

Clostridium difficile Infection: New Insights Into Management

Khanna

Pardi

2012

Mayo Clinic Proceedings

123

113

View full text Add to dashboard Cite

show abstract

“…In the first year after LTX, CF patients are 2-3 times more susceptible to C. difficile -associated diarrhoea and colitis than non-CF patients [141]. Severe colitis is a rare but classical cause of death in CF LTX recipients [142, 143]. C. difficile infection, however, may establish also after years mostly in the context of intensified immunosuppression due to graft rejection [144].…”

Section: Postoperative Carementioning

confidence: 99%

Practical Guidelines: Lung Transplantation in Patients with Cystic Fibrosis

Hirche¹,

Knoop

Hebestreit

et al. 2014

Pulmonary Medicine

View full text Add to dashboard Cite

There are no European recommendations on issues specifically related to lung transplantation (LTX) in cystic fibrosis (CF). The main goal of this paper is to provide CF care team members with clinically relevant CF-specific information on all aspects of LTX, highlighting areas of consensus and controversy throughout Europe. Bilateral lung transplantation has been shown to be an important therapeutic option for end-stage CF pulmonary disease. Transplant function and patient survival after transplantation are better than in most other indications for this procedure. Attention though has to be paid to pretransplant morbidity, time for referral, evaluation, indication, and contraindication in children and in adults. This review makes extensive use of specific evidence in the field of lung transplantation in CF patients and addresses all issues of practical importance. The requirements of pre-, peri-, and postoperative management are discussed in detail including bridging to transplant and postoperative complications, immune suppression, chronic allograft dysfunction, infection, and malignancies being the most important. Among the contributors to this guiding information are 19 members of the ECORN-CF project and other experts. The document is endorsed by the European Cystic Fibrosis Society and sponsored by the Christiane Herzog Foundation.

show abstract

“…Recurrent CDAD has been described in patients with CF, but this entity is not fully characterized in the available literature and presents a challenge to the clinician. Its occurrence can lead to prolonged antimicrobial treatment, and novel treatment options such as intravenous immunoglobulin or stool transplantation have been given [10]. Table 2 demonstrates that 9 of our 10 patients had previous (i.e.…”

Section: Discussionmentioning

confidence: 98%